Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
View/ Open
Date
2022-11-12ICR Author
Author
Lorimer, C
Cheng, L
Chandler, R
Garcez, K
Gill, V
Graham, K
Grant, W
Sardo Infirri, S
Wadsley, J
Wall, L
Webber, N
Wong, KH
Newbold, K
Type
Journal Article
Metadata
Show full item recordAbstract
AIMS: Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a median survival of 4 months. Recent advances in molecular profiling have shown that up to half of ATCs harbour the BRAF-V600E mutation. The aim of this study was to provide real-world data and experience on the use of combination therapy dabrafenib and trametinib in patients with BRAF-V600E-mutated advanced ATC. MATERIALS AND METHODS: We retrospectively evaluated patients with confirmed BRAF-V600E-mutated ATC, defined as patients with locally advanced or metastatic ATC with no locoregional, radical treatment options. Outcomes measured were overall survival, progression-free survival, response rate, discontinuation rate, dose reduction rate and toxicity data. RESULTS: Seventeen patients were evaluated and the mean age was 68 years. Ten patients died by the time of censoring. The median duration of follow-up was 12 months (3-43 months). The estimated median overall survival was 6.9 months (95% confidence interval 2.46 months - upper confidence interval not reached) and the median progression-free survival was 4.7 months (95% confidence interval 1.4-7.8 months). Dose interruptions and/or reductions were common, but none of the patients had to permanently discontinue treatment because of toxicities. Severe toxicities (grades 3 and 4) were uncommon. CONCLUSIONS: This study supports the indication of dabrafenib and trametinib in BRAF-V600E-mutated ATC as an effective and well-tolerated treatment in an historically difficult to treat cancer.
Collections
Subject
BRAF mutation
anaplastic thyroid cancer
dabrafenib
trametinib
Research team
Targeted Therapy
Language
eng
Date accepted
2022-10-25
License start date
2022-11-12
Citation
Clinical Oncology, 2022, pp. S0936-6555(22)00512-X -
Publisher
ELSEVIER SCIENCE LONDON